Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F.
Bazinet A, et al. Among authors: wang w, wang sa.
Blood Adv. 2023 Jul 11;7(13):3284-3296. doi: 10.1182/bloodadvances.2022009391.
Blood Adv. 2023.
PMID: 36884300
Free PMC article.